World's Best Scientists 2026 revealed!
Véronique Diéras

Véronique Diéras

D-Index & Metrics

Medicine

D-Index
95
Citations
49750
World Ranking
9875
National Ranking
302

Overview

Véronique Diéras is affiliated with the Institute Curie in France, focusing on oncology and breast cancer research. Their work spans the domains of medicine, with a particular emphasis on oncology, pulmonary and respiratory medicine, cancer research, genetics, and molecular biology.

Their research concentrates on multiple key topics including advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast cancer treatment studies, cancer immunotherapy and biomarkers, PARP inhibition in cancer therapy, and cancer genomics and diagnostics.

Frequent publication venues for their work include Annals of Oncology, Cancer Research, Journal of Clinical Oncology, European Journal of Cancer, and ESMO Open.

Coauthors who have regularly collaborated with Véronique Diéras include Hope S. Rugo, Javier Cortés, Delphine Loirat, Florence Dalenc, and Christelle Lévy.

Notable recent papers authored or coauthored by Véronique Diéras include:

  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis, 2021, Annals of Oncology
  • Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial, 2023, Nature Medicine
  • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study, 2021, JNCI Journal of the National Cancer Institute

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Stephen Johnston;John Pippen;Xavier Pivot;Mikhail Lichinitser

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Véronique Diéras;David Miles;Sunil Verma;Mark Pegram

  • Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

    Joanne L. Blum;Véronique Dieras;Patricia Mucci Lo Russo;John Horton

  • A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

    Elisabetta Marangoni;Anne Vincent-Salomon;Nathalie Auger;Armelle Degeorges

  • 進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)

    F Cardoso;E Senkus;A Costa;E Papadopoulos

  • Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

    Fabrice André;Fabrice André;Thomas Bachelot;Frederic Commo;Mario Campone

  • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    Martine Piccart-Gebhart;Eileen Holmes;Jośe Baselga;Evandro De Azambuja

  • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

    J Maltzman;Marck Pegram;Saeed Sadeghi;Cristina Oliva

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Mario Campone
Mario Campone Grenoble Alpes University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Bernard Asselain
Bernard Asselain Institute Curie
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Anne Vincent-Salomon
Anne Vincent-Salomon Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're drawn to the field of medicine but considering alternative pathways beyond a traditional MD program, there are several respected online degree options to explore. Many students pursue healthcare administration as a leadership-focused path, and the top online mha programs that are cahme accredited offer flexible options with rigorous standards.

Registered nurses looking to advance their credentials may be interested in online rn to bsn no clinicals pathways, which are tailored for working professionals and eliminate the requirement of additional in-person clinicals. For those already holding a master’s degree, the demand for advanced nurse practitioners has led to the emergence of the quickest dnp program tracks, helping you earn a Doctor of Nursing Practice in less time.

Affordability is also a growing concern for many students. Exploring the cheapest dnp programs can help you find budget-friendly options without compromising on quality. Online healthcare degrees can open doors to diverse roles in patient care, education, administration, and research—helping you make a real impact in the medical field.

Best Scientists Citing Véronique Diéras

Trending Scientists